Extensive research has gone into the development of RP-G28, including over 12 years of meticulous testing and evaluation of over 15,000 lactose intolerant individuals. This evaluation was accomplished by Ritter’s ability to collaborate and bring together leading experts in lactose intolerance from around the world. RP-G28 will effectively stand out as the first FDA-approved drug for the treatment of lactose intolerance.

The treatment application utilizes a gel capsule which is taken daily for 34 days. After this administration, an individual regains the ability to digest lactose long-term. Only periodical “booster” cycles are needed thereafter.

RP-G28 works by adapting the colon to break down lactose, thereby providing long-term symptom relief.